Cancer Supportive Care Products Market Expansion Continues, with Forecast Valuation of $27.01 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Cancer Supportive Care Products Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size for cancer supportive care products has seen consistent growth. The market is estimated to increase from $21.56 billion in 2024 to $22.47 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 4.2%. The upward trend observed in the historical period is due to several factors, including rising instances of cancer, heightened consciousness and education about the disease, advancements in healthcare infrastructure, an expanding elderly population, as well as improved awareness leading to timely detection.

Cancer Supportive Care Products Market Size Forecast: What's the Projected Valuation by 2029?
The market size for cancer supportive care products is anticipated to experience consistent growth over the coming years, expanding to $27.01 billion by 2029 with a compound annual growth rate (CAGR) of 4.7%. Driving this growth during the forecast period are factors such as an increase in cancer cases, an emphasis on patient-focused methods, heightened funding in cancer research, an increased emphasis on personalized medicine, and improved cancer survival rates. Notable trends reflecting in the forecast period involve technological improvements, sophisticated drug delivery systems, breakthrough drug formulations, custom care solutions, and the emergence of biodegradable products.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-products-global-market-report

What Are the Drivers Transforming the Cancer Supportive Care Products Market?
The surge in cancer cases is predicted to spur the expansion of the cancer supportive care products market in the future. The likelihood of cancer increases as people age due to cellular transformations and extended exposure to risk factors. Furthermore, habits like smoking, unhealthy eating, inactivity, and excessive drinking substantially raise cancer risks. Cancer supportive care products, which manage symptoms and enhance patient quality of life during treatment, respond to the rising demand due to increased cancer occurrence. For instance, in January 2024, the American Cancer Society, a United States non-profit organization committed to eradicating cancer, anticipated 58,450 cases of oral cavity and pharynx cancer. This projection marks a 7.2% increase from the 54,540 cases in 2023. Hence, the increasing prevalence of cancer is set to stimulate the growth of the cancer supportive care products market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18529&type=smp

What Are the Key Trends Driving Cancer Supportive Care Products Market Growth?
Leading organizations in the market for cancer supportive care products are prioritizing advancements in cancer treatments, specifically a targeted radioligand therapy (RLT) framework, to improve treatment effectiveness, minimize side effects, and enhance overall patient results. A targeted radioligand therapy (RLT) platform employs radio-marked molecules that attach to specific cancer cell markers, providing localized radiation to selectively kill cancer cells while preserving healthy tissue. For instance, in May 2022, Novartis AG, a pharmaceutical corporation headquartered in Switzerland, achieved US Food and Drug Administration (FDA) approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to use in the treatment of adult patients suffering from prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has progressed despite previous treatments. Pluvicto stands as the first FDA-endorsed targeted radioligand therapy (RLT) for eligible mCRPC patients, integrating a targeting ligand with a therapeutic radioisotope. Additionally, the FDA has approved Locametz (gallium Ga 68 gozetotide injection), utilized in PET scans to identify PSMA-positive lesions, aiding in the detection and location of cancer metastasis and determining suitability for Pluvicto therapy.

Which Segments in the Cancer Supportive Care Products Market Offer the Most Profit Potential?
The cancer supportive care products market covered in this report is segmented -

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor
2) By Indication: Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, ovary* Cancer, Melanoma Cancer, Other Indications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies

Subsegments
1) By Nonsteroidal Anti-Inflammatory Drugs (Nsaids): Ibuprofen, Aspirin, Naproxen
2) By Anti-Infective: Antibiotics, Antifungal Drugs, Antiviral Drugs
3) By Anti-Emetics: 5-Ht3 Antagonists (Ondansetron), Nk1 Antagonists (Aprepitant), Corticosteroids (Dexamethasone)
4) By Monoclonal Antibodies: Rituximab, Trastuzumab, Bevacizumab
5) By Erythropoietin Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa
6) By Opioid Analgesics: Morphine, Fentanyl, Oxycodone
7) By Bisphosphonates: Zoledronic Acid, Pamidronate, Ibandronate
8) By Granulocyte Colony Stimulating Factor: Filgrastim, Pegfilgrastim

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18529&type=smp

Which Firms Dominate the Cancer Supportive Care Products Market by Market Share and Revenue in 2025?
Major companies operating in the cancer supportive care products market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Becton Dickinson and Company, Teva Pharmaceutical Industries Limited, Baxter International Inc., Daiichi Sankyo Company Limited, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Kyowa Hakko Kirin Co. Ltd., QIAGEN N.V., Exelixis Inc., Fagron Group B.V., Tessa Therapeutics Pte Ltd., Mirati Therapeutics Inc., APR Applied Pharma Science Research S.A., Acacia Pharma Ltd., Arquer Diagnostics Ltd.

Which Regions Offer the Highest Growth Potential in the Cancer Supportive Care Products Market?
North America was the largest region in the cancer supportive care products market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer supportive care products market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18529

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.